Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the nomination of ISM2196, an AI-driven, potential best-in-class small molecule WRN inhibitor targeting advanced metastatic microsatellite instability (MSI) cancers guided by synthetic lethality strategy.
‘A bottomless pit’: How out-of-pocket TMJ costs drive patients into debt
Over three decades of relentless pain, Jonna Tallant has tried about every TMJ treatment: mouthguards, six sets of braces, dental crowns and appliances, drugs, physical
July 11, 2024